Bioelectrical impedance analysis as a clinical marker of health status in adult patients with benign gastrointestinal disease : A systematic review
Copyright © 2023 The Author(s). Published by Elsevier Ltd.. All rights reserved..
BACKGROUND: Body composition reflects nutritional status, disease status and progression, and treatment responses. Mounting evidence supports the use of bioelectrical impedance analysis (BIA) as a non-invasive tool to assess body composition. Patients with benign gastrointestinal (GI) disease experience disease-related alterations in their body composition, and bioimpedance outcomes in patients with benign GI diseases have not previously been summarized. We aimed to evaluate BIA as a clinical body composition marker for benign GI diseases and describe its association with physical health status.
METHODS: We systematically searched PubMed, Scopus, Web of Science, Embase, and CINAHL from inception to October 2023 (PROSPERO registration: CRD42021265866). Of 971 screened studies, 26 studies were included in the final analysis, comprising a total of 2398 adult patients with benign GI disease. The main outcome was raw impedance data.
RESULTS: The most frequently reported BIA outcome was phase angle (PhA) (reported in 18 of 26 studies), followed by fat-free-mass (FFM) (reported in 13 of 26 studies). The consensus view of the included studies illustrates that BIA can be a useful tool for evaluating body composition in patients with benign GI diseases, and low PhA and FFM were associated with increased nutritional risk, abnormal physical characteristics, and increased mortality risk.
CONCLUSION: To fully utilize BIA as a clinical marker of health in patients with benign GI disease, standardized protocols specific to this population are needed and prospective studies testing cut-offs and ranges, accuracy, and other raw BIA parameters for classifying disease status.
| Medienart: |
E-Artikel |
|---|
| Erscheinungsjahr: |
2024 |
|---|---|
| Erschienen: |
2024 |
| Enthalten in: |
Zur Gesamtaufnahme - volume:59 |
|---|---|
| Enthalten in: |
Clinical nutrition ESPEN - 59(2024) vom: 30. Feb., Seite 387-397 |
| Sprache: |
Englisch |
|---|
| Beteiligte Personen: |
Quist, Josephine Reinert [VerfasserIn] |
|---|
| Links: |
|---|
| Themen: |
Adult |
|---|
| Anmerkungen: |
Date Completed 16.01.2024 Date Revised 11.04.2024 published: Print-Electronic Citation Status MEDLINE |
|---|
| doi: |
10.1016/j.clnesp.2023.12.145 |
|---|
| funding: |
|
|---|---|
| Förderinstitution / Projekttitel: |
|
| PPN (Katalog-ID): |
NLM367109484 |
|---|
| LEADER | 01000caa a22002652 4500 | ||
|---|---|---|---|
| 001 | NLM367109484 | ||
| 003 | DE-627 | ||
| 005 | 20240412232718.0 | ||
| 007 | cr uuu---uuuuu | ||
| 008 | 240115s2024 xx |||||o 00| ||eng c | ||
| 024 | 7 | |a 10.1016/j.clnesp.2023.12.145 |2 doi | |
| 028 | 5 | 2 | |a pubmed24n1373.xml |
| 035 | |a (DE-627)NLM367109484 | ||
| 035 | |a (NLM)38220401 | ||
| 035 | |a (PII)S2405-4577(23)02370-7 | ||
| 040 | |a DE-627 |b ger |c DE-627 |e rakwb | ||
| 041 | |a eng | ||
| 100 | 1 | |a Quist, Josephine Reinert |e verfasserin |4 aut | |
| 245 | 1 | 0 | |a Bioelectrical impedance analysis as a clinical marker of health status in adult patients with benign gastrointestinal disease |b A systematic review |
| 264 | 1 | |c 2024 | |
| 336 | |a Text |b txt |2 rdacontent | ||
| 337 | |a ƒaComputermedien |b c |2 rdamedia | ||
| 338 | |a ƒa Online-Ressource |b cr |2 rdacarrier | ||
| 500 | |a Date Completed 16.01.2024 | ||
| 500 | |a Date Revised 11.04.2024 | ||
| 500 | |a published: Print-Electronic | ||
| 500 | |a Citation Status MEDLINE | ||
| 520 | |a Copyright © 2023 The Author(s). Published by Elsevier Ltd.. All rights reserved. | ||
| 520 | |a BACKGROUND: Body composition reflects nutritional status, disease status and progression, and treatment responses. Mounting evidence supports the use of bioelectrical impedance analysis (BIA) as a non-invasive tool to assess body composition. Patients with benign gastrointestinal (GI) disease experience disease-related alterations in their body composition, and bioimpedance outcomes in patients with benign GI diseases have not previously been summarized. We aimed to evaluate BIA as a clinical body composition marker for benign GI diseases and describe its association with physical health status | ||
| 520 | |a METHODS: We systematically searched PubMed, Scopus, Web of Science, Embase, and CINAHL from inception to October 2023 (PROSPERO registration: CRD42021265866). Of 971 screened studies, 26 studies were included in the final analysis, comprising a total of 2398 adult patients with benign GI disease. The main outcome was raw impedance data | ||
| 520 | |a RESULTS: The most frequently reported BIA outcome was phase angle (PhA) (reported in 18 of 26 studies), followed by fat-free-mass (FFM) (reported in 13 of 26 studies). The consensus view of the included studies illustrates that BIA can be a useful tool for evaluating body composition in patients with benign GI diseases, and low PhA and FFM were associated with increased nutritional risk, abnormal physical characteristics, and increased mortality risk | ||
| 520 | |a CONCLUSION: To fully utilize BIA as a clinical marker of health in patients with benign GI disease, standardized protocols specific to this population are needed and prospective studies testing cut-offs and ranges, accuracy, and other raw BIA parameters for classifying disease status | ||
| 650 | 4 | |a Systematic Review | |
| 650 | 4 | |a Journal Article | |
| 650 | 4 | |a Research Support, Non-U.S. Gov't | |
| 650 | 4 | |a Adult | |
| 650 | 4 | |a Bioelectrical impedance | |
| 650 | 4 | |a Gastrointestinal disease | |
| 650 | 4 | |a Humans | |
| 650 | 4 | |a Impedance | |
| 650 | 4 | |a Nutritional assessment | |
| 650 | 7 | |a Biomarkers |2 NLM | |
| 700 | 1 | |a Rud, Charlotte Lock |e verfasserin |4 aut | |
| 700 | 1 | |a Brantlov, Steven |e verfasserin |4 aut | |
| 700 | 1 | |a Ward, Leigh C |e verfasserin |4 aut | |
| 700 | 1 | |a Dahl Baunwall, Simon Mark |e verfasserin |4 aut | |
| 700 | 1 | |a Hvas, Christian Lodberg |e verfasserin |4 aut | |
| 773 | 0 | 8 | |i Enthalten in |t Clinical nutrition ESPEN |d 2015 |g 59(2024) vom: 30. Feb., Seite 387-397 |w (DE-627)NLM250070626 |x 2405-4577 |7 nnns |
| 773 | 1 | 8 | |g volume:59 |g year:2024 |g day:30 |g month:02 |g pages:387-397 |
| 856 | 4 | 0 | |u http://dx.doi.org/10.1016/j.clnesp.2023.12.145 |3 Volltext |
| 912 | |a GBV_USEFLAG_A | ||
| 912 | |a GBV_NLM | ||
| 951 | |a AR | ||
| 952 | |d 59 |j 2024 |b 30 |c 02 |h 387-397 | ||